Febrile Neutropenia Market Forecasts and Growth, 2016-2024

Press Release

Febrile neutropenia is defined as the development of fever with sign of infection. Febrile neutropenia is one of the most severe complications during cancer chemotherapy and is mainly caused by infectious agents like gram positive and gram negative bacteria. This diseased condition significantly reduces white blood cell count of the patients. Blood test is helpful to determine the number of white blood cells and to diagnose febrile neutropenia disease. Additionally, patient with febrile neutropenia is treated with prophylactic antibiotics to recover from persistent or recurrent fever conditions. 


The market of febrile neutropenia is majorly driven by the efforts of key players to develop novel and cost effective therapeutics. For example, in July 2014, Taiho Pharmaceutical Co., Ltd. filled an application for approval of ZOSYN 2.25 and ZOSYN 4.5 (generic name- tazobactam piperacillin) for additional indication of febrile neutropenia. This product is a combination of antibacterial β-lactamase inhibitor and can be used intravenously. Moreover, in April 2014, Amgen, Inc. collaborated with ONS Edge, Inc. to help educate nurses regarding the patients who are at the risk of febrile neutropenia. 


Browse More Detail Information About This Report At https://transparencymarketresearch.com/febrile-neutropenia-market.html

Thus, these types of efforts will build healthy platform to develop the market of febrile neutropenia hence stimulates the market growth. Additionally, large number of therapeutics under clinical pipelines by key companies will further stimulate the market growth in near future. Positive initiatives by North American and European governments will further drive the market growth of febrile neutropenia. For example, in September 2013, U.S. Food Drug and Administration (U.S. FDA) approved phase III study of Neulasta (pegfilgrastim) by Amgen, Inc. This study demonstrates increase of white blood cells in patients who are undergoing myelo-suppressive chemotherapy. In addition, in June 2010, Nivestim (TM), a new biosimilar filgrastim by Hospira, Inc. is approved by European Commission. This drug is mainly used for the prevention of febrile neutropenia and offers cost-effective treatment option for neutropenia. However, lack of specific treatment that enables to treat all the symptoms of this disorder may restrain the growth of this market. In addition, high generic competition among the key players leads to price erosion and ultimately restrains the overall growth of febrile neutropenia market.


The market of febrile neutropenia can be segmented on the basis of:

By Therapeutics Molecule Types Pegfilgrastim Vancomycin hydrochloride Filgrastim biosimilars Pegfilgrastim biosimilars Stimuxen Others

Geographically, North America dominates the global febrile neutropenia market. High degree of therapeutic needs for febrile neutropenia coupled with presence of large number of key players like Amgen, Inc., Aequus BioPharma, Inc. and others in North American market will drive the growth of the market. Europe is considered as the second largest market of febrile neutropenia. Large pool of patients under the diagnosis of this disease coupled with increasing demand of treatment fuels the growth of febrile neutropenia market. In addition, Asia-Pacific region is considered as an emerging market for febrile neutropenia due to the launch of novel drugs with improved efficacy by key companies. In addition, growing awareness for this disorder among the people will further stimulate the growth of febrile neutropenia market in Asia-Pacific region.

Request Brochure of This Report at https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2857&source=atm


Some of the key players in the febrile neutropenia market include Xenetic Biosciences plc, Richter Gedeon Nyrt., Amgen, Inc., Hospira, Inc., Eli Lilly and Company, USV Limited, Aequus BioPharma, Inc., Taiho Pharmaceutical Co., Ltd. and others.


This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include  North America  Asia Pacific  Europe Rest of the World  

This report provides comprehensive analysis of  Market growth drivers  Factors limiting market growth Current market trends  Market structure Market projections for upcoming years 

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis. 


Reasons for Buying this Report This report provides pin-point analysis for changing competitive dynamics It provides a forward looking perspective on different factors driving or restraining market growth  It provides a six-year forecast assessed on the basis of how the market is predicted to grow  It helps in understanding the key product segments and their future It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments  It provides distinctive graphics and exemplified SWOT analysis of major market segments 

Request For Discount On This Report At https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=2857&source=atm


Related Articles